-
公开(公告)号：US11891437B2
公开(公告)日：2024-02-06
申请号：US17392943
申请日：2021-08-03
Applicant: Genentech, Inc.
Inventor： Amin Famili , Germaine Fuh , Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal
CPC classification number: C07K16/22 , A61K9/0014 , A61K9/0019 , A61K9/0048 , A61K9/06 , A61K9/08 , A61K47/61 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号：US10906968B2
公开(公告)日：2021-02-02
申请号：US16033353
申请日：2018-07-12
Applicant: Genentech, Inc.
Inventor： Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C12N15/10 , C12N15/115 , C07K16/22 , A61K47/60 , A61K47/61 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , A61K39/00
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号：US10072075B2
公开(公告)日：2018-09-11
申请号：US15274612
申请日：2016-09-23
Applicant: Genentech, Inc.
Inventor： Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C07K16/22 , A61K39/395 , A61K47/34 , C07K14/475 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115 , A61K47/60 , A61K47/61 , A61K39/00
CPC classification number: C07K16/22 , A61K39/3955 , A61K47/34 , A61K47/60 , A61K47/61 , A61K2039/505 , A61K2039/54 , C07K14/475 , C07K16/44 , C07K16/468 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N15/1037 , C12N15/115 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
Patent Agency Ranking
公开(公告)号：US12006360B2
公开(公告)日：2024-06-11
申请号：US16860891
申请日：2020-04-28
Applicant: Genentech, Inc.
Inventor： Germaine Fuh , Chingwei V. Lee , Patrick Koenig
IPC: A61K39/395 , A61K45/06 , C07K16/24 , C07K16/46 , A61K39/00
CPC classification number: C07K16/244 , A61K39/3955 , A61K45/06 , C07K16/247 , C07K16/468 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/92
Abstract: The invention provides dual specific antibodies capable of binding interleukin 4 (IL4) and interleukin 5 (IL5) and methods of making and using such antibodies. In general, the dual specific antibodies capable of binding IL4 and IL5 are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected.
-
公开(公告)号：US10683348B2
公开(公告)日：2020-06-16
申请号：US15167030
申请日：2016-05-27
Applicant: Genentech, Inc.
Inventor： Germaine Fuh , Chingwei V. Lee , Patrick Koenig
IPC: C07K16/32 , C07K16/28 , C07K16/22 , C07K16/42 , C07K16/46 , A61K39/00 , C07K16/24 , A61K39/395 , A61K45/06
Abstract: The invention provides dual specific antibodies and methods of making and using such antibodies. In general, the dual specific antibodies are generated by identification of a monospecific antibody having light chain variable region VL residues that are electrostatic or hydrophobic and altering the nucleic acid sequence encoding one or more solvent accessible residues in the VH of the antibody either alone or in combination with alteration of the nucleic acid sequence encoding the VL of the antibody. The altered VH and the VL are expressed and dual specific antibodies, or antigen-binding fragments thereof, are selected. Exemplary dual specific antibodies are also provided as well as methods of using the antibodies.
-
公开(公告)号：US12121586B2
公开(公告)日：2024-10-22
申请号：US17129251
申请日：2020-12-21
Applicant: Genentech, Inc.
Inventor： Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C40B30/04 , A61K39/395 , A61K47/34 , A61K47/60 , A61K47/61 , C07K14/475 , C07K16/22 , C07K16/44 , C07K16/46 , C12N15/10 , C12N15/115 , A61K39/00
CPC classification number: A61K47/61 , A61K39/3955 , A61K47/34 , A61K47/60 , C07K14/475 , C07K16/22 , C07K16/44 , C07K16/468 , C12N15/1037 , C12N15/115 , C40B30/04 , A61K2039/505 , A61K2039/54 , C07K2317/14 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/90 , C07K2317/92 , C07K2317/94 , C07K2318/20 , C07K2319/30 , C07K2319/31 , C12N2310/16
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
公开(公告)号：US11111291B2
公开(公告)日：2021-09-07
申请号：US16572822
申请日：2019-09-17
Applicant: Genentech, Inc.
Inventor： Amin Famili , Germaine Fuh , Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal
Abstract: The present invention provides antibody conjugates that include antibodies (e.g., anti-VEGF antibodies) covalently linked to polymers (e.g., hyaluronic acid (HA) polymers), cysteine engineered antibodies, pharmaceutical compositions thereof, and uses thereof, for example for treatment of disorders associated with pathological angiogenesis (e.g., ocular disorders).
-
公开(公告)号：US10899828B2
公开(公告)日：2021-01-26
申请号：US16033499
申请日：2018-07-12
Applicant: Genentech, Inc.
Inventor： Patrick Koenig , Chingwei Vivian Lee , Karthikan Rajagopal , Amin Famili , Germaine Fuh
IPC: C07K16/22 , A61K47/61 , A61K39/395 , C07K16/44 , C07K16/46 , A61K39/00 , A61K47/60 , A61K47/34 , C07K14/475 , C12N15/10 , C12N15/115
Abstract: The present invention provides anti-VEGF antibodies and compositions that include anti-VEGF antibodies (e.g., antibody conjugates, fusion proteins, and polymeric formulations), and uses thereof, for example for treatment of disorders associated with pathological angiogenesis. The present invention also provides methods of identifying antibody variants with improved properties, for example, enhanced binding affinity, stability, pharmacokinetics, and/or expression.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.01 seconds)
